Special Discounts on Group Registration | Heart Congress 2018

We would like to welcome University Professors/Associate Professors/Assistant Professors and their students, Company Head/Manager/CEO with their Company Employees/Staffs in groups to participate at Heart Congress 2018 and get an idea of the latest research and innovation that are taking place in the field of cardiology and connect with the experts under a single roof.

Groups Strength can contain 4-5 Members 

Privileges for Groups:

• Provide a platform to organize symposia or workshops
• Special interactive sessions will be provided
• Promotion of their labs will be feasible
• Recognition for that particular University/Industry in our future Conferences     

Register and get 20% Discount on Groups...... 

To Register and book your slot, Please Visit: https://bit.ly/2q0wQEC 

#HeartCongress2018   #ThisAugust   #Osaka

Chance to Visit Osaka, Japan at Best Prices | Heart Congress 2018 | August 20-21, 2018

Explore the beauty of #Osaka 

#Osaka_Attractions    #HeartCongress2018    #ThisAugust

Local Attraction Includes

1.     Dotonbori

2.     Osaka Aquarium Kaiyukan

3.     Universal Studios Japan

4.     Osaka Castle Park

5.     Tempozan Ferris Wheel

6.     Ebisu Bridge

7.     Kuchu Teien Observatory

8.     Tennoji Zoo and Many more to explore……….

Visit  : https://bit.ly/2FBnhTa

#HeartCongress2018    

#Top_Cardiologists   #Physicians   # Surgeons   #Under_A_Single_Roof

Management of Heart Failure in Hypertrophic Cardiomyopathy

The following are key points to remember on the clinical spectrum and management of heart failure (HF) in hypertrophic cardiomyopathy (HCM):

1. HCM is the most common genetic heart disease, diverse in phenotypic expression and natural history, characterized by well recognized largely treatable complications, including highly visible risk for sudden death.
2. Demographics and epidemiology of HCM have evolved, with the pendulum swinging toward greater recognition of functional disability due to exertional dyspnea (and fatigue), traditionally regarded as a form of HF. HF, characterized by excessive exertional dyspnea, is now a common complication of HCM.
3. There are a number of important differences in the prevalence, clinical profile, pathophysiology, management, and outcome of HCM patients with HF compared to the larger population of non-HCM patients with conventional congestive HF.
4. HCM-related HF is most commonly due to dynamic mechanical impedance to left ventricular (LV) outflow produced by mitral valve systolic anterior motion, leading to high intracavity pressures.
5. HF in HCM is associated with diverse and complex pathophysiology with a substantially more favorable prognosis than conventional non-HCM HF, and highly amenable to effective treatment options in the vast majority of patients.
6. Traditional pharmacologic strategies to control or reduce exertional symptoms in HCM have been largely empiric, based on retrospective observational studies. Drug treatment has consisted primarily of beta-blockers and calcium antagonists (predominantly verapamil), which improve LV filling, but do not significantly reduce outflow gradients at rest.
7. Surgical septal myectomy with low operative mortality (<1%) produces HF reversal and symptom relief in 90-95% of patients, while also conveying a survival benefit.
8. In accordance with American College of Cardiology/American Heart Association guidelines, alcohol ablation is considered a therapeutic alternative to myectomy in selected patients, particularly those of advanced age or with comorbidities.
9. Exercise echocardiography has assumed an important role in the evaluation of HCM patients, by identifying candidates for septal reduction therapy with refractory HF when outflow gradients are present only with physiologic exercise, distinguishing highly symptomatic nonobstructive patients as heart transplant candidates, and predicting future development of progressive HF.
10. Treatment for advanced HF has acquired an increasingly prominent profile within the HCM disease spectrum, leading to transplant as the only definitive treatment option in a small minority of nonobstructive patients.

For more Details -->  https://bit.ly/2FBnhTa

#HeartCongress2018  #ThisAugust   #Osaka_Japan

Call For Abstract | Heart Congress 2018

#Call_For_Abstract

Abstract Submission Phase I Open | Submit Soon and get the opportunity to share your Latest research Work in front of top Cardiologists from all over the globe

Highlights :

#Cardiology    #CVD    #Pharmacologyof   #HF      #HeartSurgery     #Cardiomyopathy #RearDiseases    #CardiacNursing       #CardiacDiagnosticTest   &      #More…..

You can drop your interest regarding participation to –

heartsurgery[at]pulsusconference[dot]com

or You can visit link for more details : https://heartcongress.pulsusconference.com/call-for-abstracts 

#HeartCongress2018  #Osaka_Japan  #ThisAugust

Register Soon to avail full Benefits - Early Bird Countdown | Heart Congress 2018

Early bird takes the worms!!! 

Register on or before April 30, 2018 to avail full benefits of early bird. 

Book your slots and Confirm your presence soon

Group Discount Available with special Benefits. 

To Discuss more drop us a mail to heartsurger[at]pulsusconference[dot]com